Found 167 clinical trials
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy …
- 6 views
- 18 Sep, 2023
- 190 locations
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
This clinical trial assesses whether a newly designed algorithm which looks at the genomic signature of each patient's tumor to predict their sensitivity to standard of care treatment verses being placed on a personally designed treatment trial can improve the responses in patients with newly diagnosed triple-negative breast cancer (TNBC). …
- 3 views
- 26 May, 2022
- 5 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …
- 1041 views
- 16 Sep, 2023
- 107 locations
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
subjects must have intact Rb, identified at the time of screening, by immunohistochemistry testing of submitted tumor specimen. Subjects will receive Abemaciclib 200 mg twice daily until progression or
- 11 views
- 08 Apr, 2023
- 5 locations
BBPA PET/CT in Patients With Malignant Tumors
multiple examination, histopathology, molecular pathology and LAT-1 immunohistochemistry will also be obtained.
- 0 views
- 19 Aug, 2023
- 1 location
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
immunohistochemistry assay and examine the relationship with response to therapy. Perform pharmacogenomics analyses of drug metabolism and transport proteins through germline DNA examination.
- 1 views
- 22 Oct, 2022
- 1 location
Effects of Intrauterine Administration of Autologous PBMC Modulated With IFNt on Endometrial Cell Populations
following month. Immunohistochemistry analysis of the cell composition of the endometrium will be performed.
- 0 views
- 07 Apr, 2023
- 1 location
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
immunohistochemistry in HER2 negative breast cancer after treatment with ADG106 alone and in combination with chemotherapy. Secondary Objectives To determine the efficacy of combination of
- 0 views
- 02 Jul, 2022
- 1 location
![[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma](/media/imagery/281458.svg)
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
HIF2α immunohistochemistry (IHC). There will be two cohorts. The first pre-surgical cohort will have [18F]PT2385 PET/CT prior to nephrectomy. The uptake and retention on Positron Emission Tomography
- 0 views
- 07 Oct, 2022
- 1 location
Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer (VENEZO-LUNG)
) and Overall response rate (ORR) The translational substudy will include: Analysis of tumor tissue samples will consist of PD-L1 Immunohistochemistry testing, RNA expression, Work
- 0 views
- 07 Jul, 2022
- 3 locations